Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.40 |
| ▸ | SKP1 | P63208 | 2/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920256 | 0.83 | KCNH2 (0.42) | KCNH2GBA1KITCKS1BSKP1 | |
| SCHEMBL2918433 | 0.77 | GBA1 (0.56) | GBA1KITCKS1BSKP1SKP2 | |
| SCHEMBL25388799 | 0.76 | GBA1 (0.47) | GBA1KITCKS1BSKP1SKP2 | |
| SCHEMBL2919286 | 0.74 | PDGFRB (0.62) | KCNH2KITTLR9PDGFRBACHE | |
| SCHEMBL2924122 | 0.74 | PDGFRB (0.51) | KITPDGFRBKDM4EMAPT | |
| SCHEMBL27241086 | 0.70 | GBA1 (0.48) | GBA1KITCKS1BSKP1SKP2 | |
| SCHEMBL27241077 | 0.70 | GBA1 (0.51) | GBA1KITCKS1BSKP1SKP2 | |
| SCHEMBL13876175 | 0.68 | ACHE (0.43) | KCNH2KITCKS1BSKP1SKP2 | |
| SCHEMBL2923711 | 0.68 | KIT (0.51) | KCNH2KITTLR9PDGFRBKDM4E | |
| SCHEMBL13876151 | 0.67 | KCNH2 (0.44) | KCNH2GBA1KITCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | KCNH2 2868/4885GBA1 3789/4885KIT 2045/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | KCNH2 2667/4885GBA1 4122/4885KIT 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.